Three-dimensional printing in structural heart disease and intervention

Yiting Fan, Randolph H. L. Wong, Alex Pui-Wai Lee

Division of Cardiology, Department of Medicine and Therapeutics, Division of Cardiothoracic Surgery, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China

Contributions: (I) Conception and design: Y Fan, AP Lee; (II) Administrative support: AP Lee, RH Wong; (III) Provision of study materials or patients: Y Fan; AP Lee; (IV) Collection and assembly of data: Y Fan; (V) Data analysis and interpretation: Y Fan; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Alex Pui-Wai Lee, MD, FRCP, FACC, FESC. Rm 114037, 9/F, Lui Che Woo Clinical Sciences Building, Prince of Wales Hospital, Shatin, N.T., Hong Kong, China. Email: alexpwlee@cuhk.edu.hk.

Abstract: Three-dimensional (3D) printing refers to the process by which physical objects are built by depositing materials in layers based on a specific digital design. It was initially used in manufacture industry. Inspired by the technology, clinicians have recently attempted to integrate 3D printing into medical applications. One of the medical specialties that has recently made such attempt is cardiology, especially in the field of structural heart disease (SHD). SHD refers to a group of non-coronary cardiovascular disorders and related interventions. Obvious examples are aortic stenosis, mitral regurgitation, atrial septal defect, and known or potential left atrial appendage (LAA) clots. In the last decade, cardiologists have witnessed a dramatic increase in the types and complexity of catheter-based interventions for SHD. Current imaging modalities have important limitations in accurate delineation of cardiac anatomies necessary for SHD interventions. Application of 3D printing in SHD interventional planning enables tangible appreciation of cardiac anatomy and allows in vitro interventional device testing. 3D printing is used in diagnostic workup, guidance of treatment strategies, and procedural simulation, facilitating hemodynamic research, enhancing interventional training, and promoting patient-clinician communication. In this review, we attempt to define the concept, technique, and workflow of 3D printing in SHD and its interventions, highlighting the reported clinical benefits and unsolved issues, as well as exploring future developments in this field.

Keywords: Three-dimensional printing (3D printing); structural heart disease (SHD); cardiovascular intervention; cardiovascular imaging

Submitted Aug 31, 2019. Accepted for publication Sep 11, 2019.

doi: 10.21037/atm.2019.09.73

View this article at: http://dx.doi.org/10.21037/atm.2019.09.73

Introduction

Three-dimensional (3D) printing, also known as rapid prototyping, additive manufacturing, or solid freeform technology, refers to the process by which physical objects are built by depositing materials in layers based on a specific digital design (1). This technology was first introduced by Jean Claude André, who subsequently abandoned the patent application, and Charles Hull in 1984, who coined the term “stereolithography” (SLA) and later co-founded 3D System Corporation. It was initially used in manufacture industry to create 3D models from digital images to allow users testing on a design before investment into larger scale manufacturing (2). Freedom of design, mass customization, waste minimization, and the ability to manufacture complex structures are the main advantages of SLA as a technology of manufacturing, which have made it widely adopted by various crafts and design industries (3). Inspired by the technology, clinicians have recently attempted to integrate 3D printing into medical applications, taking advantage of its merits of advanced visualization and procedural simulation to improve...
Clinical practice. Dental, maxillofacial, and orthopaedic surgeons were among the first to pioneer the use of medical 3D printing. Cumulative experience from these specialties has encouraged cardiologists and other clinicians to enter the field.

Structural heart disease (SHD) refers to a group of non-coronary cardiovascular disorders and related interventions. Obvious examples are aortic stenosis, mitral regurgitation (MR), atrial septal defect (ASD), and known or potential left atrial appendage (LAA) clots. In the last decade, cardiologists have witnessed a dramatic increase in the types and complexity of catheter-based interventions for SHD. Compared to cardiac surgeons, interventional cardiologists cannot directly visualize or palpate the anatomy during catheter-based intervention, and rely heavily on imaging to understand complex anatomy (4).

Unfortunately, current imaging modalities have important limitations in accurate delineation of cardiac anatomies. 2D-imaging, for instance, falls short both in representation of the complicated 3D relationships as well as assistance of corrective procedures (5). The physicians have to mentally reconstruct 2D images in different imaging planes to appreciate complex 3D spatial relationships (6). Although advances in 3D imaging enable display of 3D images, it is still only displayed on flat computer screens. Application of 3D printing in SHD interventional planning enables tangible appreciation of cardiac anatomy and allows *in vitro* interventional device testing (7). Application of 3D printing in SHD may answers to the pressing need for understanding the pathology and optimization of cardiac procedures for individual patients.

In SHD, 3D printing is used in diagnostic workup, guidance of treatment strategies (7,8), and procedural simulation (9-11), facilitating hemodynamic research (12,13), enhancing interventional training, and promoting patient-clinician communication (14,15). Herein, we present a contemporary review to define the concept, technique, and work flow of medical 3D printing, highlighting the reported clinical benefits and unsolved issues, as well as exploring future developments in this field.

### Cardiovascular image data acquisition

The protocol of 3D printing generally involves 3 steps: image acquisition, data post-processing, and manufacturing (*Figure 1*). Typical data source for medical 3D printing are volumetric medical image data sets (16). An imaging data set must be volumetric with high-spatial resolution and minimal artefact which allows non-ambiguous separation of the region of interest from surrounding structures/blood pool. Moreover, dynamic datasets are preferred since they provide temporal resolution that allows selection of the optimal phase in cardiac cycle for printing (4). The most commonly used imaging sources for SHD are echocardiography (17,18), computed tomography (CT) (16,19) and magnetic resonance imaging (MRI) (20,21). Other modalities, such as positron emission tomography, single photon emission CT and cone beam CT, are less commonly used (22). All images should use the common Digital Imaging and Communication in Medicine (DICOM) format (23,24).

#### CT

The advantages of high spatial resolution, high image quality, and relatively easy image segmentation make CT the most commonly used modality for 3D printing (25-27). The use of CT contrast increases the signal-to-noise ratio of images, enabling convenient separation of the region of interest from surrounding structures during image segmentation. The timing of contrast injection is crucial for adequacy of CT images for 3D printing. Image segmentation may become difficult or non-feasible contrast opacification of structures is inadequate, or blooming artefacts created by metallic implants and/or calcifications are present. Cardiac CT has several limitations including radiation and nephrotoxic contrast exposure, and thus may not be the imaging modality of choice in paediatric patients or patients with renal insufficiency.

#### 3D echocardiography (3DE)

3DE, especially 3D transesophageal echo (TEE), is an attractive image data source for 3D printing. It is widely available, relatively low-cost, and does not require ionizing radiation (28). In mitral and tricuspid valve procedures, echocardiography rather than CT is often the primary imaging modality for preprocedural screening, intraprocedural monitoring, and postprocedural follow-up. 3DE has the highest temporal resolution among all 3D imaging modalities, allowing selection of images at the optimal timing in the cardiac cycle for 3D printing (29). Because contrast is generally not used during 3DE, segmentation techniques for 3DE relies on contrast in echogenic intensity of different tissues against the blood pool. For tissue structures surrounded by blood pool, such
Figure 1 Pre-procedural simulation of MitraClip on 3D-printed model. (A) Digital model of a heart. Different colors stand for different cardiac components (grey: mitral valves; light pink: tricuspid valves; light gold: atrial septum, left atrium, left and right ventricle). (B) Multi-material 3D-printed heart model for pre-procedural simulation. The valves were printed with flexible material and the rests were printed with hard material. (C) The 5 holes drilled in the atrial septum represents the different position for different kinds of structural heart interventions. (D) The MiraClip device was released via delivery catheter through the atrial septum to the mitral valve. Blue circle: MitraClip; red circle: left atrial appendage occlusion (LAAO). S, superior; A, anterior; P, posterior; I, inferior; IVC, inferior vena cava; LAA, left atrial appendage; MV, mitral valve.

as valves and the atrial septum, direct thresholding to create a tissue mask is sufficient to create 3D models (17). For hollow structures such as the LAA, indirect segmentation of blood pool can separate the region of interest from the surroundings (30). Blood volume of the hollow structure is segmented first, and then a geometric surface mesh model of the hollow cast is refined to extract the internal structures.

There are limitations of 3DE as an imaging source for 3D printing. 3DE has a narrow field of view relative to CT or MRI (29). As a result, 3D models of the whole heart cannot be easily created in by 3DE-based 3D printing. In case of LAA closure, for instance, 3D-TEE based 3D printing usually cannot include the atrial septum in the LAA model, hence the procedural step of transseptal puncture in LAA occlusion cannot be simulated. Furthermore, the signal-to-noise ratio of 3DE is relatively low compared to CT. More manual adjustments are needed during image segmentation, which may lead to more error and lower reproducibility, especially for fine structural details in the far field of 3DE images.

Cardiac MRI

Compared to 3DE and CT, cardiac MRI is of limited use for 3D printing. First, a full MRI scanning often takes over an hour to complete. During the scanning, patients are required to lie still and follow breath-holding commands intermittently. Therefore, it poses challenge to complete a cardiac MRI scan for patients with poor compliance, such as elderly and those with frailty and comorbidities (4). Sometimes an additional usage of sedation is required. Moreover, patients who have prior implantation of internal ferromagnetic devices are forbidden from entering the MRI machine. Second, similar to 3DE, MRI have a narrow field of view, thus may require specific scan protocols such as 3D
full-phase navigated MRI when multiple structures are to be printed. Lastly, the slice thickness with minimal 3 mm of MRI is suboptimal, falling short in providing detailed replication in coronary arteries and valves; on the other hand, MRI is increasingly used in reconstruction of cardiac mass, congenital heart diseases and systemic vasculature disorders (20,21,31).

Post-processing of image data

The second step in generation of a 3D-printed model is an image data post-processing procedure known as segmentation using dedicated image post-processing software (22). This process involves the automated or semi-automated delineation of the structures of interest and conversion to digital models of geometric meshwork. Segmentation requires comprehensive knowledge of the cardiac anatomy, image interpretation, and skills in using the image post-processing software (32). Several algorithms are available to perform image segmentation, the most frequently used being multi-planar reformation, region growing, surface/volume rendering, and maximal/minimal intensity projection (22).

During segmentation, the contours of the region of interest are identified on multiple 2D image planes and computationally transformed into 3D triangular surface
meshwork. These data are usually stored and exported in standard tessellation language (STL) format, which can be sent to 3D printers for printing. The digital models generated at this stage are usually anamorphic and rough, which have to be further refined and optimized using computer-aided design software for 3D printing. The most frequently used digital model refinement techniques include surface smoothing, trimming, hollowing, and patching. Apart from being used for creation of 3D physical models, the digital models so generated can also be used for digital simulation of virtual procedures and device implantation on computer screen. The tissue-device interaction can be quantitively evaluated with the aid of analysis software (33-35).

**Creation of 3D-printed models**

The final step of 3D printing is fabrication of the physical models by 3D printers. Several printing techniques are available and the appropriate one(s) should be chosen according to the purpose of the application. In cardiovascular applications, widely used 3D printing techniques include fused deposition modelling (FDM), selective laser sintering (SLS), SLA, and material jetting (36). Other techniques such as injection molding, inkjet/extrusion/laser-assisted bioprinting are seldom used in cardiovascular specialty.

Although various kinds of materials can be used in medical 3D printing, scant data exist for the mechanical properties of these materials compared with real cardiovascular tissues. Recently, some rubber-like 3D printing materials with capability of repeated flexing and bending are proved to have similar mechanical properties with cardiovascular tissues (37). Silicon has excellent resemblance to soft tissue; however, it is technically impossible to use silicon as printing material like rubbers or metals. The only feasible way of producing silicone models is injection molding (38). However, silicone is too soft and easily to be torn. It is now more commonly applied to the solid models or models with hard support. When it comes to the organs with big cavities but thin walls, such as atriums and vessels, the precise duplication is difficult to be realized.

Multi-material printing by material jetting is increasingly used to create cardiac structures. Different tissue components were printed with different textures. For instance, an aortic valve was printed with flexible printing material, and the calcifications attached to valves were printed with hard printing material, respectively.

**Applications of 3D printing in SHD interventions**

SHD refers to a wide range of non-coronary cardiac conditions and related interventions (39). The increasing complexity for SHD interventions and the limitations of current imaging modalities make 3D printing a potential game-changer in procedural planning. The application of 3D printing has several notable advantages. First, it helps to ease pre-procedural planning by providing anatomic prototype models of high accuracy. The 3D-printed physical model can be hold on hands and inspected from full range of views, allowing excellent spatial appreciation of complex cardiovascular pathologies (40,41). The tactile perception of models enables better understanding of anatomy and improved confidence in procedural planning, minimizing visual errors caused by 2D images (42). Second, in vitro procedural simulation on model provides guidance in catheter and device selection during the procedure. This may result in shortening of procedural time, reduction in device resizing, and decrease in radiation exposure (43). It also potentially helps to avoid procedural complications and improving procedural efficacy (44). Lastly, these life-sized models may reduce the learning curve of the interventional operators and enhance patient-clinician interactions (19) (Table 1).

**LAA occlusion**

Catheter-based LAA occlusion is an alternative to anticoagulation for stroke prevention in patients with non-valvular atrial fibrillation (62). The complexity of LAA anatomy has been overlooked until recent development in LAA occlusion reminding us its heterogeneous and complex morphology. Planning of LAA occlusion usually uses peri-procedural 2D-TEE combining with fluoroscopy guidance and, less frequently, with pre-procedural CT. The unique and variable anatomy of the LAA poses a challenge for accurate sizing of the device. Reportedly 1.5% to 9.1% of cases fail to achieve implant success (63), and serious complications, in particular pericardial effusion, are reported in 4% of procedures (62,64). Moreover, residual peri-device leak and device thrombus have been implicated in late thromboembolic events on long-term follow-up (65).

Successful implantation of the LAA device depends on accurate sizing of device landing zone and precise catheter positioning at the appropriate depth and orientation before device release (66). Patient-specific 3D-printed models allows detail assessment of the shape of the appendage,
size of the ostium, angulation of the appendage body, and location of the trabeculations (19,40,67). Besides, these models allow pre-procedural simulation of different sizes and types of devices, and can serve as guidance of device implantation strategy during the procedure. Device sizing guided by 3D printing is associated with improved procedural outcomes (37,45). With the aid of software for 3D strain analysis, device-model interactions can be quantified in vitro (67). Potential complications such as peri-device leak and pericardial effusion resulting from incorrect sizing can be avoided. In addition to device selection, 3D printing allows fabrication of customized LAA devices as recently reported by Mosadegh’s team (47). Their work offers an alternative solution in challenging cases with LAA morphologies incompatible with commercially available devices.

**Transcatheter aortic valve implantation (TAVI)**

TAVI has established as an alternative treatment for symptomatic severe aortic stenosis in candidates who are considered high risk for receiving traditional open-heart surgery (68,69). The procedure has not gained much attention until 2010s when positive results of the PARTNER trials were reported (70,71). It is now generally accepted as a safe procedure preferred by patients, with its indications and patient volume expected to rapidly expand in near future. Procedural success in TAVI requires rigorous screening for suitable patients with a good understanding of how the transcatheter heart valve prosthesis, when deployed, would seat in the aortic root of the patients (72), especially in patients with complex aortic anatomy such as a porcelain aorta (73). 3D models allow direct visualization of valve pathology and hands-on simulation by physicians (9,49). More importantly, pre-procedural simulation on 3D models can identify potential complications in complex cases (74) (Figure 2A,B,C).

In a case series reported by our group (75), procedural simulation on 3D-printed aortic root models enables pre-procedural prediction and post-procedural investigation of the mechanisms of coronary occlusion, a rare but potentially fatal TAVI complication in patients with high-risk anatomy (i.e., low-lying coronary ostium, small aortic root, valve-in-valve implantation). In a patient reported by Lee et al. (76), procedural simulation on 3D model predicts and unveils the mechanism of coronary obstruction caused by displacement of the bulky calcified left cusp of the aortic valve by the self-expanding prosthesis towards the left coronary ostium. Moreover, simulations on patient-specific 3D-printed models can predict the occurrence of post-TAVI paravalvular leaks in the actual procedure (50,51). Qian et al. demonstrated the feasibility of using 3D printed aortic root phantoms composed of tissue-mimicking materials to quantify post-TAVI aortic root strain in vitro; the proposed annular bulge index achieved a high level of accuracy in predicting severity and locations of post-TAVI paravalvular leaks (50). In addition to anatomic information, fabricated patient-specific aortic valve models can be coupled to pulsatile flow loop hemodynamic simulators to assess the functional characteristics of the valve under various controlled forward flow conditions (52). Such simulation platforms are potentially useful for physiologic evaluation of the stenotic aortic valve and hemodynamic consequence of aortic valve implantation such as TAVI.

**Transcatheter mitral valve intervention (TRAMI)**

According to a population-based study (77,78), MR is the most frequent valve disease with a prevalence of 9.3% in patients ≥75 years old. Until recently, for elderly patients or patient with co-morbidities who are deemed inoperable or high risk for conventional surgery, effective treatment option has been lacking. With the advances in transcatheter techniques and devices, less invasive TRAMI for MR has become available (72). There are currently two main TRAMI approaches. The first approach is transcatheter mitral valve repair. The most widely adopted transcatheter repair technique is the MitraClip™ system (Abbott; Santa Clara, CA, USA), which is a catheter-based edge-to-edge leaflet repair technique. During the MitraClip™ procedure, a clip-like device is deployed through a transfemoral transseptal approach to the mitral leaflets, recreating leaflet coaptation to achieve MR reduction. The worldwide volume of this procedure is constantly growing (79). The second TRAMI approach is transcatheter mitral valve replacement, in which a bioprosthetic valve is delivered in the mitral position to replace the diseased one (80). These less invasive percutaneous techniques are attractive treatment alternatives for severe MR in patients deemed high risk for conventional surgery.

As the anatomy of mitral valve is more complex than that of aortic valve, successful procedural planning for TRAMI requires even more individualized assessment than TAVI. The introduction of 3D printing in TRAMI has revolutionized how cardiologists understand mitral valve anatomy and predict the impact of various interventions.
### Table 1 Characteristics of applications of 3D printing in different cardiovascular scenarios

<table>
<thead>
<tr>
<th>Cardiovascular scenario</th>
<th>Imaging source(s)</th>
<th>3D printing technologies</th>
<th>3D printing materials</th>
<th>Advantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left atrial appendage (LAA) occlusion</td>
<td>TEE (37,40,45,46)</td>
<td>Material jetting (47)</td>
<td>Tango+, Tango Plus (46,47)</td>
<td>Allowance for advanced visual and tactile examination (19,37,40,45,46,48)</td>
</tr>
<tr>
<td></td>
<td>CT, CTA (19,45-48)</td>
<td>Fused deposition modelling (40,47)</td>
<td>Agilus (37)</td>
<td>Aid in peri-procedural diagnosis, planning and simulation, and intra-procedural guidance (19,37,40,45,46,48)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stereolithography (19,37,40,45-48)</td>
<td>VeroClear (47)</td>
<td>Customized implants for personalized treatment (47)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Silicone (40)</td>
<td>Elimination of early implanter learning curve (19)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Composite elastomeric material comprising Silane, polycarbonate urethane (PCU), Silicone (47)</td>
<td>Associated with improvement of procedural safety and efficacy, as well as better clinical outcome (37)</td>
</tr>
<tr>
<td>Transcatheter aortic valve implantation (TAVI)</td>
<td>CT, CTA (9,49-52)</td>
<td>Material jetting (51)</td>
<td>Vero White Plus (52)</td>
<td>Advanced visualization and diagnosis (9,49-52)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stereolithography (50,52)</td>
<td>Tango Plus (52)</td>
<td>Planning and simulation of procedures (9,49-52)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Quantitative prediction of procedural complications (50,51)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Education and patient-clinician communication (9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Customized leaflet design (51)</td>
</tr>
<tr>
<td>Transcatheter mitral valve intervention (TRAMI)</td>
<td>TEE (18,53-55)</td>
<td>Fused deposition modelling (55)</td>
<td>N/A</td>
<td>Advanced visualization and diagnosis (18,34,53-57)</td>
</tr>
<tr>
<td></td>
<td>CT, CTA (34,56,57)</td>
<td>Stereolithography (18,53,54,56,57)</td>
<td></td>
<td>Planning and simulation of procedures (34,56,57)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Prediction of procedural complications (34)</td>
</tr>
<tr>
<td>Isolated and complex congenital heart disease (ASD and VSD)</td>
<td>TEE (44)</td>
<td>Stereolithography (44,58-61)</td>
<td>Tango Plus (44,60)</td>
<td>Patient screening (58,61)</td>
</tr>
<tr>
<td></td>
<td>CT, CTA (58-61)</td>
<td></td>
<td>Vero Plus (44)</td>
<td>Advanced visualization and diagnosis; (44,58,60,61)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ZR80 photoreactive resin polylactic acid (61)</td>
<td>Planning and simulation of procedures (44,58-61)</td>
</tr>
</tbody>
</table>

3D, three-dimensional; CT, computed tomography; CTA, computed tomography angiography; TEE, transesophageal echo; ASD, atrial septal defect; VSD, ventricular septal defect.
on the mitral valve. It complements conventional imaging in patient and device selection. Effects of various TRAMI techniques on the mitral valve apparatus can be better appreciated through device simulation on tissue-mimicking 3D models (81) and complications not predicted by conventional imaging can potentially be revealed (82). 3D modelling may have a role in innovating personalized approach to treat complex MR lesions combing multiple different devices (56). 3D simulated models predict left ventricular outflow tract obstruction in patients undergoing transcatheter mitral valve replacement prompting anterior mitral leaflet resection and alcohol septal ablation prior to procedure (83).

**Congenital heart diseases**

Congenital heart diseases occur in approximately 1% of live births. ASD are among the most common form of congenital heart diseases. Therapeutic intervention of ASD has evolved from open heart surgery to percutaneous therapy with closure devices. Percutaneous closure of secundum ASD is highly feasible and safe. Imaging with echocardiography is used to guide these procedures with excellent long-term outcome (84,85). Closure of multiple or fenestrated ASD, or complex residual peri-device defects, however, require more careful planning. 3D printing can help in precise location of the anatomic landmarks which may not be appreciated adequately on conventional imaging modalities, and facilitate selection of device size with pre-procedural simulation. Primary imaging data sources for 3D printing in ASD and other congenital heart disease include CT (58), echocardiography (17), and cardiac MRI (86). 3D models provide vivid demonstration of the defects and their 3D relations with surrounding structures. Importantly, 3D model simulation aids to assess whether there are sufficient tissue rims for secure device anchor (58). In a patient with partial device prolapse after percutaneous ASD closure and recurrent left-to-right interatrial shunt around the rim of the first device, 3D printing parts with multiple materials proved to be advantageous by allowing realistic procedural planning on structures consisting of soft cardiac tissues and rigid implanted prosthesis (44) (*Figure 2D,E,F,G*).

**Unresolved issues and future direction**

Despite the enthusiasm in applying 3D printing cardiovascular medicine, there remains several issues that need to be resolved before widespread adoption of this technology. Current limitation of 3D printing includes the lack of validated technical standard, increased upfront costs of the technology, and scant evidence on the added clinical benefit.

The accuracy of replication of the cardiac structural geometry must be validated across different source imaging modalities, 3D printing methods, and cardiovascular modelling scenarios. Standardizations of the source image data acquisition protocol and image post-processing techniques are important. Although different imaging modalities are complementary and generally show good correlations in anatomic measurements, the results have been limited to small case series (87-89). Therefore, more head-to-head comparisons are needed to provide data for developing standard protocols. A streamlined workflow is needed so extra schedule for additional imaging acquisitions can be avoided before 3D printing (90).

There are different types of 3D printers that vary in printing techniques used, materials employed for printing, time-to-print, learning curve, cost, and finish quality of the product. The most frequently reported 3D printing technologies in cardiovascular medicine include FDM, SLS, SLA, and material jetting. The accuracy and reproducibility (intra- and inter-operator variability) of clinical 3D-printed models generated by different printing technologies need to be validated and compared before wide incorporation into clinical practice. Such comparisons are lacking particularly in the field of cardiovascular 3D printing in SHD interventions. The mechanical properties of the 3D-printed materials, such as tensile strength, elasticity, flexibility, hardness, and durability have utmost importance for cardiovascular applications (56). The majority of cardiovascular applications reported so far have employed materials with properties that have not been meticulously compared with the cardiovascular tissue they are mimicking. Validation of 3D-printed material properties against actual human patient tissues is important to ensure that procedural simulation is realistic.

Cost is a major barrier to widespread adoption of 3D printing. Most of the cost in 3D printing can be attributed to dedicated hardware and software, 3D printers, materials, and labour. The learning curve of 3D printing for clinical and engineering users remains a major challenge since interpretation of cardiac anatomy and pathology from different imaging source and image post-processing and operation of the 3D printing require both medical and engineering expertise. Communications between clinicians and engineers regarding the specific clinical demands and available technical solutions for individual cases remain
the key to success in implementation of 3D printing in clinical care.

Last but not least, the added benefits of 3D printing in terms of improvement in clinically meaningful outcomes need to be systematically defined in clinical studies. There is a growing body of evidence linking the use of 3D printing as guidance of SHD intervention with improved procedural outcomes (37,45,91). Randomized clinical trials are warranted to provide robust outcome data on the effect of 3D printing on procedural efficacy and safety, procedural time, patient-physician communication, as well as the cost-effectiveness of the technology.

Conclusions

Cardiovascular 3D printing is a novel tool that has the potential to revolutionize the planning of SHD intervention. With the rapid increase in the availability and variety of percutaneous therapies and devices in SHD, it is imperative that interventional cardiologists are able to have a deep understanding of the spatial relationship of complex cardiovascular anatomy in SHD. The advent of 3D printing technology is able to create anatomically accurate, patient-specific physicals model, converting virtual 3D images on flat computer screen to palpable 3D models suited for interventional simulation. Patient-specific 3D-printed models of cardiovascular structures have emerged as promising tools for pre-procedural planning, intra-procedural decision making, and post-procedural evaluation of the mechanisms of procedure-related complications should they occur. Nevertheless, widespread clinical adoption of 3D printing in SHD interventions is currently limited owing to the lack of robust evidence that systematically demonstrates the effectiveness, technical barrier, and increased upfront cost. Further effort in technical standardization, and clinical evaluation of added benefit and cost-effectiveness of 3D printing are needed to bring this promising technique to clinical reality.

Acknowledgments

Funding: This work was funded by the Hong Kong Special Administrative Region Government Health and Medical Research Fund (No. 05160976).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References


64. Reddy VY, Holmes D, Doshi SK, et al. Safety of


